InMed Pharmaceuticals (INM)
(Delayed Data from NSDQ)
$2.20 USD
-0.04 (-1.78%)
Updated Aug 8, 2025 01:41 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
INM 2.20 -0.04(-1.78%)
Will INM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for INM based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for INM
InMed to Present INM-901 Data at Alzheimer's Association International Conference (AAIC) 2025 | ...
InMed Pharmaceuticals (INM) Files to Sell 3.9 Million Common Shares | INM Stock News
InMed Pharmaceuticals registers 3.9M shares for resale
InMed Pharmaceuticals files to sell 3.9M common shares for holders
InMed Pharmaceuticals Secures $5 Million in Private Placement to Advance Drug Pipeline